Badreldin Hisham A, Alsuhebany Nada, Alzahrani Mohammed, Alshehri Abdulmajeed M, Aldoughaim Maha, Alqifari Saleh, Yassin Omar, Alfehaid Lama, Alqahtani Tariq
Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Curr Res Pharmacol Drug Discov. 2024 Mar 14;6:100179. doi: 10.1016/j.crphar.2024.100179. eCollection 2024.
Direct Oral Anticoagulants (DOACs) have revolutionized the treatment of thromboembolic disorders, offering targeted, effective, and safer alternatives to traditional anticoagulants like heparins and vitamin K antagonists (VKAs). Despite their benefits, DOACs have drawbacks, including an increased risk of gastrointestinal bleeding and unsuitability for patients with mechanical heart valves. Recent research has highlighted Factor XI (FXI) as a promising anticoagulation target due to its significant role in pathological thrombosis and minor involvement in normal hemostasis. Abelacimab, an antibody that inhibits FXI, has shown potential in transforming anticoagulation therapy by sparing hemostasis. This review provides a comprehensive analysis of abelacimab, examining its clinical pharmacology and its pharmacokinetic and pharmacodynamic properties. It scrutinizes abelacimab's safety profile and key monitoring parameters. The current evidence supporting its use and potential future research strengthening its position in anticoagulant therapy is also discussed. The objective is to enhance understanding and contribute to discussions around developing safer anticoagulants, particularly for patients at risk for thrombosis.
直接口服抗凝剂（DOACs）彻底改变了血栓栓塞性疾病的治疗方式，为肝素和维生素K拮抗剂（VKAs）等传统抗凝剂提供了有针对性、有效且更安全的替代方案。尽管DOACs有诸多益处，但也存在缺点，包括胃肠道出血风险增加以及不适用于机械心脏瓣膜患者。最近的研究强调，由于因子XI（FXI）在病理性血栓形成中起重要作用且在正常止血中作用较小，因此它是一个有前景的抗凝靶点。阿贝西单抗是一种抑制FXI的抗体，已显示出通过保留止血功能来改变抗凝治疗的潜力。本综述对阿贝西单抗进行了全面分析，研究了其临床药理学以及药代动力学和药效学特性。它仔细审查了阿贝西单抗的安全性概况和关键监测参数。还讨论了支持其使用的现有证据以及加强其在抗凝治疗中地位的潜在未来研究。目的是增进理解，并为围绕开发更安全的抗凝剂的讨论做出贡献，特别是对于有血栓形成风险的患者。
